Tebubio and MileCell Partner to Distribute Research Tools
The agreement provides European researchers with direct access to MileCell's ADME-Tox biological models and reagents.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you believe corporate research partnerships lead to better drug development outcomes?
Tebubio has partnered with San Diego-based MileCell Biotechnology to distribute the company's full research portfolio across Europe. This agreement combines MileCell's biological products with Tebubio's local scientific support infrastructure.
Why it matters
The partnership expands the range of biological models and specialized research tools available to European laboratories, specifically accelerating procurement for ADME-Tox studies.
The catalog includes primary cells like hepatocytes and Kupffer cells alongside subcellular fractions, such as microsomes and S9, used in drug metabolism research. These are supported by specialized reagents including MagSep nanomagnetic beads and Kryogene cell freezing media.
The players
Tebubio
A European distributor specializing in laboratory services and biological products for research.
MileCell Biotechnology
A San Diego-based manufacturer of primary cells, subcellular fractions, and biospecimens for drug discovery.
The details
MileCell Biotechnology specializes in the production of primary cells—biological cells taken directly from living tissue—and subcellular fractions, which are isolated components of cells used to simulate human metabolic pathways. These models are critical for ADME-Tox research, the process of evaluating the Absorption, Distribution, Metabolism, Excretion, and Toxicity of new drug candidates. By integrating these products into its existing European network, Tebubio provides researchers with localized technical expertise alongside the physical distribution of these biospecimens.
Timeline
October 27, 2026: Official announcement of the distribution partnership.
The Tech Race
The deal reflects a broader trend of bridging regional gaps in the drug discovery pipeline by improving access to standardized primary cell models. It aligns with global efforts to provide consistent, high-quality biological materials to labs competing in early-stage pharmaceutical development.
European researchers can now access MileCell's full catalog of homogenates and PBMCs through local Tebubio offices rather than sourcing them internationally. This integration is designed to reduce logistical friction and provide onsite technical support for complex assays.
The takeaway
This partnership standardizes the availability of specialized primary cell models for European research teams. Investigators should track the upcoming product catalog updates on the Tebubio portal to determine if these specific biospecimens can replace current in-house isolation protocols.
Further reading
For more on the evolving infrastructure for laboratory research, visit our Biotech section.
Source note: This article includes information reported by Biotech-spain.
Live Poll
Do you believe corporate research partnerships lead to better drug development outcomes?
